Endometrioid ovarian cancer and endometriotic cells exhibit the same alteration in the expression of interleukin-1 receptor II: To a link between endometriosis and endometrioid ovarian cancer

Journal of Obstetrics and Gynaecology Research

Volumn 37, Issue 2, 2011, Pages 99-107

  Keita, Mamadou ^a   AinMelk, Youssef ^a   Pelmus, Manuella ^a   Bessette, Paul ^a   Aris, Aziz ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Endometrial cells; Endometrioid ovarian cancer cells; Endometriosis; Interleukin 1; Interleukin 1 receptors (IL 1 R1 IL 1R2); Ovarian cancer subtypes

Indexed keywords

INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II;

ARTICLE; CONTROLLED STUDY; ENDOMETRIOSIS; ENDOMETRIUM CELL; ENDOMETRIUM TUMOR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; ENDOMETRIOSIS; ENDOMETRIUM; EPITHELIAL CELLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMANS; IMAGE CYTOMETRY; OVARIAN DISEASES; OVARIAN NEOPLASMS; RECEPTORS, INTERLEUKIN-1 TYPE I; RECEPTORS, INTERLEUKIN-1 TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79955944677     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2010.01320.x     Document Type: Article

References (46)

1. Zhang X, Feng J, Ye X, Yao Y, Zhou P, Chen X. Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer. Gynecol Oncol 2006; 103: 848-852. (Pubitemid 44821302)
2. Tagashira Y, Shimada M, Kigawa J, Iba T, Terakawa N. Ovarian endometrioid adenocarcinoma arising from endometriosis in a young woman. Gynecol Oncol 2003; 91: 643-647. (Pubitemid 38388166)
3. Kurman RJ, Craig JM. Endometrioid and clear cell carcinoma of the ovary. Cancer 1972; 29: 1653-1664.
4. Oral E, Ilvan S, Tustas E et al. Prevalence of endometriosis in malignant epithelial ovary tumours. Eur J Obstet Gynecol Reprod Biol 2003; 109: 97-101. (Pubitemid 36724650)
5. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004; 4: 641-648. (Pubitemid 39025049)
6. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78. (Pubitemid 38082155)
7. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cells 2005; 7: 211-217. (Pubitemid 40568680)
8. Apte RN, Dotan S, Elkabets M et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumorhost interactions. Cancer Metastasis Rev 2006; 25: 387-108.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867. (Pubitemid 36019639)
10. Kharfi A, Akoum A. Correlation between decreased type-II interleukin-1 receptor and increased monocyte chemotactic protein-1 expression in the endometrium of women with endometriosis. Am J Reprod Immunol 2001; 45: 193-199. (Pubitemid 32236773)
11. Townson DH, Pate JL. Regulation of prostaglandin synthesis by interleukin-1 beta in cultured bovine luteal cells. Biol Reprod 1994; 51: 480-485. (Pubitemid 24297620)
12. Hurwitz A, Finci-Yeheskel Z, Dushnik M et al. Cytokine- mediated regulation of rat ovarian function: Interleukin-1 inhibits plasminogen activator activity through the induction of plasminogen activator inhibitor-1 (PAI-1). Mol Cell Endocrinol 1994; 101: 307-314. (Pubitemid 24132803)
13. Kokia E, Hurwitz A, Ben-Shlomo I, Adashi EY, Yanagishita M. Receptor-mediated stimulatory effect of IL-1 beta on hyaluronic acid and proteoglycan biosynthesis by cultured rat ovarian cells: Role for heterologous cell-cell interactions. Endocrinology 1993; 133: 2391-2394. (Pubitemid 23324752)
14. Ben-Shlomo I, Adashi EY, Payne DW. The morphogenic/ cytotoxic and prostaglandin-stimulating activities of interleukin-1 beta in the rat ovary are nitric oxide independent. J Clin Invest 1994; 94: 1463-1469. (Pubitemid 24309865)
15. Gerard N, Caillaud M, Martoriati A, Goudet G, Lalmanach AC. The interleukin-1 system and female reproduction. J Endocrinol 2004; 180: 203-212.
16. Simon C, Moreno C, Remohi J, Pellicer A. Cytokines and embryo implantation. J Reprod Immunol 1998; 39: 117-131. (Pubitemid 28418418)
17. Sheth KV, Roca GL, al-Sedairy ST, Parhar RS, Hamilton CJ, al-Abdul Jabbar F. Prediction of successful embryo implantation by measuring interleukin-1-alpha and immunosup- pressive factor(s) in preimplantation embryo culture fluid. Fertil Steril 1991; 55: 952-957.
18. Simon C, Piquette GN, Frances A, Polan ML. Localization of interleukin-1 type I receptor and interleukin-1 beta in human endometrium throughout the menstrual cycle. J Clin Endocrinol Metab 1993; 77: 549-555. (Pubitemid 23230073)
19. Akoum A, Jolicoeur C, Kharfi A, Aube M. Decreased expression of the decoy interleukin-1 receptor type II in human endometriosis. Am J Pathol 2001; 158: 481-489. (Pubitemid 32162166)
20. Burke F, Relf M, Negus R, Balkwill F. A cytokine profile of normal and malignant ovary. Cytokine 1996; 8: 578-585. (Pubitemid 26294548)
21. Punnonen R, Teisala K, Kuoppala T, Bennett B, Punnonen J. Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors. Cancer 1998; 83: 788-796. (Pubitemid 28387706)
22. Toutirais O, Chartier P, Dubois D et al. Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 2003; 14: 246-255. (Pubitemid 38122233)
23. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993; 91: 2194-2206. (Pubitemid 23141496)
24. Li BY, Mohanraj D, Olson MC et al. Human ovarian epithelial cancer cells cultures in vitro express both interleukin 1 alpha and beta genes. Cancer Res 1992; 52: 2248-2252.
25. Nishida M, Nasu K, Fukuda J, Kawano Y, Narahara H, Miyakawa I. Down-regulation of interleukin-1 receptor type 1 expression causes the dysregulated expression of CXC chemokines in endometriotic stromal cells: A possible mechanism for the altered immunological functions in endometriosis. J Clin Endocrinol Metab 2004; 89: 5094-5100. (Pubitemid 39391454)
26. Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004; 4: 378-385. (Pubitemid 38987065)
27. Kharfi A, Boucher A, Akoum A. Abnormal interleukin-1 receptor type II gene expression in the endometrium of women with endometriosis. Biol Reprod 2002; 66: 401-106.
28. Lawson C, Al-Akoum M, Maheux R, Akoum A. Increased expression of interleukin-1 receptor type 1 in active endometriotic lesions. Reproduction 2007; 133: 265-274. (Pubitemid 46332174)
29. Lawson C, Bourcier N, Al-Akoum M, Maheux R, Naud F, Akoum A. Abnormal interleukin 1 receptor types I and II gene expression in eutopic and ectopic endometrial tissues of women with endometriosis. J Reprod Immunol 2007; 2008 77: 75-84.
30. Barlow DH, Kennedy S. Endometriosis: New genetic approaches and therapy. Annu Rev Med 2005; 56: 345-356. (Pubitemid 40299787)
31. Ulukus M, Arici A. Immunology of endometriosis. Minerva Ginecol 2005; 57: 237-248. (Pubitemid 41503757)
32. Akoum A, Lawson C, McColl S, Villeneuve M. Ectopic endometrial cells express high concentrations of interleukin (IL)-8 in vivo regardless of the menstrual cycle phase and respond to oestradiol by up-regulating IL-1-induced IL-8 expression in vitro. Mol Hum Reprod 2001; 7: 859-866. (Pubitemid 32842754)
33. Osteen KG, Igarashi TM, Yeaman GR, Bruner-Tran KL. Steroid and cytokine regulation of matrix metalloproteinases and the pathophysiology of endometriosis. Gynecol Obstet Invest 2004; 57: 53-54. (Pubitemid 38186437)
34. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci 2002; 955: 89-100. (Pubitemid 34271066)
35. Akoum A, Lemay A, Brunet C, Hebert J. Cytokine-induced secretion of monocyte chemotactic protein-1 by human endometriotic cells in culture. The Groupe d'Investigation en Gynecologie. Am J Obstet Gynecol 1995; 172: 594-600.
36. Lebovic DI, Bentzien F, Chao VA, Garrett EN, Meng YG, Taylor RN. Induction of an angiogenic phenotype in endometriotic stromal cell cultures by interleukin-1beta. Mol Hum Reprod 2000; 6: 269-275. (Pubitemid 30120622)
37. Cui X, Rouhani FN, Hawari F, Levine SJ. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopep- tidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 2003; 171: 6814-6819. (Pubitemid 37532116)
38. Colotta F, Re F, Muzio M et al. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Sciences (New York) 1993; 261: 472-475. (Pubitemid 23276556)
39. Akoum A, Lawson C, Herrmann-Lavoie C, Maheux R. Imbalance in the expression of the activating type I and the inhibitory type II interleukin 1 receptors in endometriosis. Hum Reprod 2007; 22: 1464-1473. (Pubitemid 47062820)
40. Burleson KM, Boente MP, Pambuccian SE, Skubitz AP. Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med 2006; 4: 6.
41. Wang FQ, So J, Reierstad S, Fishman DA. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 2006; 118: 879-888. (Pubitemid 43157663)
42. Elloul S, Silins I, Trope CG, Benshushan A, Davidson B, Reich R. Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch 2006; 449: 520-528. (Pubitemid 44722320)
43. Choi JH, Choi KC, Auersperg N, Leung PC. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 2006; 66: 3912-3920.
44. Ahmed N, Thompson EW, Quinn MA. Epithelial- mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: An exception to the norm. J Cell Physiol 2007; 213: 581-588. (Pubitemid 350058249)
45. Shoham Z. Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: Where are we today? Fertil Steril 1994; 62: 433-448. (Pubitemid 24273188)
46. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG. Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 1996; 65: 13-18. (Pubitemid 26006641)